Gut bacteria pill shows promise for ulcerative colitis in early trial
NCT ID NCT05852574
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 25 times
Summary
This early study tests CP101, a pill made from healthy gut bacteria, in 30 adults with mild-to-moderate ulcerative colitis. The goal is to see if the bacteria can safely take hold in the gut and help control the disease. Participants receive either a short or extended course of CP101 and are monitored for 24 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.